ERBB2 and breast cancer: We hypothesized that the addition of FDG-PET/CT to the diagnostic work-up for patients with small, HER2+ BC who were lymph node-negative on ultrasound, could improve clinical staging, leading to less nodal involvement on final pathology and better patient selection for a less intense NAST treatment schedule including PT.